Ciclib 125mg Capsule

About Ciclib 125mg Capsule

Ciclib 125mg Capsule contains Palbociclib, a targeted anticancer medication that belongs to the cyclin-dependent kinase (CDK) 4/6 inhibitor class and is used for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. This type of breast cancer occurs when cancer cells grow uncontrollably and may spread to other parts of the body. Palbociclib works by blocking specific enzymes that promote cancer cell growth and division, helping to slow disease progression and improve treatment outcomes. Ciclib 125mg Capsule is typically prescribed in combination with hormonal therapies or other anticancer medications to enhance its effectiveness. The dosage and treatment schedule are determined by the oncologist based on the patients condition, overall health, and response to therapy, and should be followed exactly as prescribed. Before starting treatment, patients should inform their healthcare provider about any existing medical conditions, liver problems, infections, or medications they are taking, as regular monitoring of blood counts and overall health is required during therapy. Common side effects may include fatigue, infections, nausea, hair thinning, mouth ulcers, decreased appetite, and low blood cell counts, which can increase the risk of infections. Regular medical follow-up and laboratory testing are essential to ensure the safe and effective use of Ciclib 125mg Capsule. By targeting the pathways responsible for cancer cell multiplication, Ciclib 125mg plays an important role in the modern management of advanced breast cancer and helps improve long-term disease control.